

# Tad A Holak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2092994/publications.pdf>

Version: 2024-02-01

86  
papers

5,479  
citations

94381

37  
h-index

82499

72  
g-index

93  
all docs

93  
docs citations

93  
times ranked

4938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanism of MyD88S mediated signal termination. <i>Cell Communication and Signaling</i> , 2022, 20, 10.	2.7	6
2	Analysis tools for single-monomer measurements of self-assembly processes. <i>Scientific Reports</i> , 2022, 12, 4682.	1.6	1
3	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. <i>Molecules</i> , 2022, 27, 3454.	1.7	5
4	Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe. <i>Pharmaceuticals</i> , 2022, 15, 697.	1.7	7
5	Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint. <i>Advanced Therapeutics</i> , 2021, 4, 2000195.	1.6	5
6	Human and mouse PD-L1: similar molecular structure, but different druggability profiles. <i>IScience</i> , 2021, 24, 101960.	1.9	45
7	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 768-773.	1.3	30
8	Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode. <i>Bioelectrochemistry</i> , 2021, 139, 107742.	2.4	18
9	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11614-11636.	2.9	42
10	Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. <i>Molecules</i> , 2021, 26, 4848.	1.7	5
11	A fragment-based approach identifies an allosteric pocket that impacts malate dehydrogenase activity. <i>Communications Biology</i> , 2021, 4, 949.	2.0	2
12	PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11797.	1.8	18
13	Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination. <i>ChemMedChem</i> , 2020, 15, 370-375.	1.6	5
14	Systematic $\alpha$ -foldamerization <sup>TM</sup> of peptide inhibiting p53-MDM2/X interactions by the incorporation of trans- or cis-2-aminocyclopentanecarboxylic acid residues. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112814.	2.6	11
15	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11271-11285.	2.9	45
16	Anti-CD44 DNA Aptamers Selectively Target Cancer Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 289-298.	2.0	13
17	Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions. <i>Molecules</i> , 2020, 25, 3017.	1.7	11
18	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions. <i>Angewandte Chemie</i> , 2020, 132, 5273-5279.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 5235-5241.	7.2	29
20	Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111588.	2.6	9
21	CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?. <i>Molecules</i> , 2019, 24, 2804.	1.7	103
22	Design, Synthesis, Evaluation, and Structural Studies of C <sub>2</sub> -Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7250-7263.	2.9	71
23	Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. <i>Cancers</i> , 2019, 11, 1014.	1.7	25
24	A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53 <sup>wt</sup> osteosarcoma cells. <i>FEBS Journal</i> , 2019, 286, 1360-1374.	2.2	13
25	Development of the Inhibitors That Target the PD-1/PD-L1 Interaction – A Brief Look at Progress on Small Molecules, Peptides and Macrocyces. <i>Molecules</i> , 2019, 24, 2071.	1.7	106
26	A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 151-170.	2.4	30
27	Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 513-520.	1.3	10
28	NMR fragment-based screening for development of the CD44-binding small molecules. <i>Bioorganic Chemistry</i> , 2019, 82, 284-289.	2.0	3
29	Identification of small-molecule inhibitors of USP2a. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 261-267.	2.6	24
30	Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 4840-4848.	7.2	109
31	Der Immuncheckpoint PD-1/PD-L1: Gibt es Therapieoptionen jenseits der Antikörper?. <i>Angewandte Chemie</i> , 2018, 130, 4932-4940.	1.6	4
32	Crystal structure of the FAS1 domain of the hyaluronic acid receptor stabilin-2. <i>Acta Crystallographica Section D: Structural Biology</i> , 2018, 74, 695-701.	1.1	5
33	Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. <i>Cancers</i> , 2018, 10, 396.	1.7	49
34	A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 665-678.	2.4	105
35	1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4234-4244.	2.9	29
36	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5857-5867.	2.9	242

#	ARTICLE	IF	CITATIONS
37	Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G <sub>0</sub> /G <sub>1</sub> Arrest by Inhibiting Deubiquitinase USP2a. <i>Cell Chemical Biology</i> , 2017, 24, 458-470.e18.	2.5	41
38	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie</i> , 2017, 129, 13920-13923.	1.6	13
39	Artificial Macrocycles as Potent p53-MDM2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1025-1030.	1.3	28
40	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 13732-13735.	7.2	131
41	Two-Step Synthesis of Complex Artificial Macrocyclic Compounds. <i>Angewandte Chemie</i> , 2017, 129, 10865-10869.	1.6	9
42	Two-Step Synthesis of Complex Artificial Macrocyclic Compounds. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 10725-10729.	7.2	37
43	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
44	Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 384-407.	2.6	30
45	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
46	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). <i>Oncotarget</i> , 2016, 7, 30323-30335.	0.8	297
47	Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 973-977.	2.4	89
48	A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction. <i>ACS Chemical Biology</i> , 2016, 11, 3310-3318.	1.6	31
49	Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay. <i>Life Sciences</i> , 2016, 145, 240-246.	2.0	17
50	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
51	Conformations and Conformational Processes of Hexahydrobenzazocines by NMR and DFT Studies. <i>Journal of Organic Chemistry</i> , 2015, 80, 9231-9239.	1.7	6
52	2,3-Bis(1H-indole) heterocycles: New p53/MDM2/MDMX antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5661-5666.	1.0	32
53	The conserved ubiquitin-like protein Hub1 plays a critical role in splicing in human cells. <i>Journal of Molecular Cell Biology</i> , 2014, 6, 312-323.	1.5	30
54	Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities. <i>ACS Chemical Biology</i> , 2014, 9, 802-811.	1.6	38

#	ARTICLE	IF	CITATIONS
55	Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 2286-2288.	7.2	62
56	Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction. <i>Structure</i> , 2013, 21, 2143-2151.	1.6	57
57	Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 425-448.	2.4	64
58	Structure of the Stapled p53 Peptide Bound to Mdm2. <i>Journal of the American Chemical Society</i> , 2012, 134, 103-106.	6.6	222
59	Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists. <i>PLoS ONE</i> , 2012, 7, e32839.	1.1	90
60	Exhaustive Fluorine Scanning toward Potent p53-Mdm2 Antagonists. <i>ChemMedChem</i> , 2012, 7, 49-52.	1.6	50
61	The p53-MDM2/MDMX axis – A chemotype perspective. <i>MedChemComm</i> , 2011, 2, 246.	3.5	68
62	Jetzt wird es ernst: strukturbasiertes Design von Mdm2/Mdmx-p53-Inhibitoren. <i>Angewandte Chemie</i> , 2011, 123, 2732-2741.	1.6	7
63	The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 2680-2688.	7.2	150
64	Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 5352-5356.	7.2	136
65	1,4-Thienodiazepine-5-diones via MCR (I): Synthesis, Virtual Space and p53-Mdm2 Activity. <i>Chemical Biology and Drug Design</i> , 2010, 76, 116-129.	1.5	63
66	Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. <i>Cell Cycle</i> , 2010, 9, 1104-1111.	1.3	217
67	High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. <i>Cell Cycle</i> , 2009, 8, 1176-1184.	1.3	98
68	Rapid and Efficient Hydrophilicity Tuning of p53/mdm2 Antagonists. <i>ACS Combinatorial Science</i> , 2009, 11, 631-639.	3.3	34
69	Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins. <i>Journal of the American Chemical Society</i> , 2009, 131, 7500-7501.	6.6	32
70	Isoquinolinone Inhibitors of the MDM2-p53 Interaction. <i>ChemMedChem</i> , 2008, 3, 1118-1128.	1.6	51
71	NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5035-5042.	2.9	12
72	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. <i>Cell Cycle</i> , 2008, 7, 2441-2443.	1.3	182

#	ARTICLE	IF	CITATIONS
73	Molecular Basis for the Inhibition of p53 by Mdmx. <i>Cell Cycle</i> , 2007, 6, 2386-2392.	1.3	132
74	An NMR-Based Antagonist Induced Dissociation Assay for Targeting the Ligand-Protein and Protein-Protein Interactions in Competition Binding Experiments. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4382-4387.	2.9	43
75	NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. <i>Nature Medicine</i> , 2005, 11, 1135-1136.	15.2	106
76	Monitoring the Effects of Antagonists on Protein-Protein Interactions with NMR Spectroscopy. <i>Journal of the American Chemical Society</i> , 2005, 127, 13220-13226.	6.6	74
77	NMR structural characterization of the N-terminal domain of the adenyl cyclase-associated protein (CAP) from <i>Dictyostelium discoideum</i> . , 2004, 29, 73.		1
78	Application of NMR in Structural Proteomics. <i>Structure</i> , 2002, 10, 1613-1618.	1.6	86
79	Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53. <i>Biochemistry</i> , 2001, 40, 336-344.	1.2	279
80	NMR 15 N relaxation of the insulin-like growth factor (IGF)-binding domain of IGF binding protein-5 (IGFBP-5) determined free in solution and in complex with IGF-II. <i>FEBS Journal</i> , 2001, 268, 1058-1065.	0.2	14
81	Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein. <i>Journal of Biomolecular NMR</i> , 2000, 17, 87-88.	1.6	21
82	Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53. <i>Journal of Biomolecular NMR</i> , 2000, 17, 91-92.	1.6	13
83	Robust refocusing of 13C magnetization in multidimensional NMR experiments by adiabatic fast passage pulses. , 1999, 15, 331-334.		11
84	NMR structural characterization of the CDK inhibitor p19INK4d. <i>FEBS Letters</i> , 1997, 401, 127-132.	1.3	25
85	The repeating segments of the F-actin cross-linking gelation factor (ABP-120) have an immunoglobulin-like fold. <i>Nature Structural Biology</i> , 1997, 4, 223-230.	9.7	75
86	NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF). <i>Protein Science</i> , 1996, 5, 2095-2103.	3.1	44